Joseph Schwartz, an analyst from Leerink Partners, reiterated the Buy rating on Insmed (INSM – Research Report). The associated price target remains the same with $100.00.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Joseph Schwartz has given his Buy rating due to a combination of factors, primarily focusing on Insmed’s promising financial performance and pipeline developments. The company reported Arikayce sales that slightly exceeded consensus expectations, indicating robust demand for their product in treating refractory Mycobacterium avium complex lung disease. Additionally, Insmed has maintained its full-year guidance for Arikayce, suggesting confidence in continued revenue growth.
Moreover, Schwartz highlights the potential of Insmed’s pipeline, particularly the upcoming regulatory milestones for brensocatib, which is under priority review by the FDA with a decision expected in August 2025. The potential market opportunity for brensocatib in non-cystic fibrosis bronchiectasis is significant, estimated at $5 billion. Furthermore, the anticipated Phase 2 data for TPIP in pulmonary arterial hypertension and the upcoming studies in other indications underscore the company’s strategic focus on expanding its therapeutic offerings. These elements contribute to Schwartz’s positive outlook on Insmed as a stable investment with growth potential.
Schwartz covers the Healthcare sector, focusing on stocks such as Wave Life Sciences, Avidity Biosciences, and Sarepta Therapeutics. According to TipRanks, Schwartz has an average return of 9.6% and a 38.91% success rate on recommended stocks.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $90.00 price target.